Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
04/2003
04/30/2003CN1413610A Compound hemorrhoidal pill and its preparation method
04/30/2003CN1413609A Chinese medicine composite for treatment and prevention of cerebral arteries obstruction
04/30/2003CN1413601A Chinese medicine for compound circulation treatment of angiocardiopathy and cerebrovascular disease
04/30/2003CN1413600A Chinese medicine preparation containing ophiopogon root total saponin and preparation method
04/30/2003CN1413594A Medicine for prevention and curing reangiostenosis
04/30/2003CN1413588A Drug composition containing Fructus Tribuli fruit total saponin and its preparation method
04/30/2003CN1107066C Diaza-spiro [3,5] nonane derivatives
04/30/2003CN1107059C Azole derivative
04/30/2003CN1107058C Subsitituted isoxazoles for treatment of inflammation
04/30/2003CN1106845C Process for preparing solid-state-microspherical vascular cuppository of sodium alginate
04/29/2003USRE38102 Use of a pyridazinone derivative
04/29/2003US6555710 Aminobenzophenones as inhibitors of IL-1 β and TNF-α
04/29/2003US6555700 1,3-propane diol esters and ethers and methods for their use in drug delivery
04/29/2003US6555675 Dinucleoside polyphosphates which facilitate secretory mechanisms, i.e. increasing the hydration of mucus secretions, stimulating the production of mucins and increasing ciliary beat frequency to facilitate clearance
04/29/2003US6555667 Hypoxia-regulated genes
04/29/2003US6555651 Ligand binding site of rage and uses thereof
04/29/2003US6555575 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
04/29/2003US6555574 Antiarrhythmic agents
04/29/2003US6555556 N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors
04/29/2003US6555542 Sulfonamide lactam inhibitors of FXa and method
04/29/2003US6555540 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
04/29/2003US6555539 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis
04/29/2003US6555535 Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors
04/29/2003US6555519 O-glucosylated benzamide SGLT2 inhibitors and method
04/29/2003US6555377 Process for production of mammalian cell lines
04/29/2003US6555352 Peptide for use in human therapeutics and diagnostic compositions
04/29/2003US6555319 Antibodies for inhibiting blood coagulation and methods of use thereof
04/29/2003US6555134 Synergistic mixtures of garlic and lycopene for preventing LDL oxidation
04/29/2003US6555105 Method of treatment with a RANTES antagonist polypeptide
04/24/2003WO2003034067A1 Modulation of tor
04/24/2003WO2003034063A1 Method of screening remedy for atrial fibrillation
04/24/2003WO2003034028A2 Methods for identifying and using modulators of estrogen related receptor gamma
04/24/2003WO2003033696A1 Vegf antisense compound
04/24/2003WO2003033680A2 Kinases and phosphatases
04/24/2003WO2003033671A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
04/24/2003WO2003033660A2 9136, a human aldehyde dehydrogenase family member and uses therefor
04/24/2003WO2003033653A2 Affinity enhancement agents
04/24/2003WO2003033535A2 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
04/24/2003WO2003033534A2 Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof
04/24/2003WO2003033528A1 Cyclic peptides as g-protein-coupled receptor antagonists
04/24/2003WO2003033527A2 Cyclosporine analogue mixtures and their use as immunomodulating agents
04/24/2003WO2003033524A2 Peptidyl ketones as inhibitors of dpiv
04/24/2003WO2003033514A1 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
04/24/2003WO2003033502A1 Bicyclic oxopyridine and oxopyrimidine derivatives
04/24/2003WO2003033501A1 Himbacine analogues as thrombin receptor antagonists
04/24/2003WO2003033495A1 Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
04/24/2003WO2003033493A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR δ
04/24/2003WO2003033484A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof
04/24/2003WO2003033483A1 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
04/24/2003WO2003033482A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors
04/24/2003WO2003033481A1 Benzoxazine and benzothiazine derivatives and parmaceutical compositions containing them
04/24/2003WO2003033478A1 Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
04/24/2003WO2003033471A1 Novel pyridone derivative and remedial agent for circulatory disease containing the same
04/24/2003WO2003033467A1 Nitroso diphenylamine derivatives as nitrogen monoxide generating agents
04/24/2003WO2003033466A1 Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
04/24/2003WO2003033457A1 Biphenyl-derivatives as p38-kinase inhibitors
04/24/2003WO2003033456A1 NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS
04/24/2003WO2003033453A1 Dicarboxylic acid derivatives, their preparation and therapeutical use
04/24/2003WO2003033445A1 Stabilized compositions of aqueous reduced coenzyme q solution
04/24/2003WO2003033029A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications
04/24/2003WO2003033023A1 Drugs ameliorating hypo-hdl cholesterolemia
04/24/2003WO2003033010A1 Cyclosporin analogs for the treatment of autoimmune diseases
04/24/2003WO2003033005A1 Concentrate comprising green tea, grape skin extract and grape seed extract, the production thereof and the use of the same
04/24/2003WO2003033002A1 Intracellular calcium concentration increase inhibitors
04/24/2003WO2003033001A1 Combinations comprising cox-2 inhibitors and aspirin
04/24/2003WO2003032999A1 Alkyne matrix metalloproteinase inhibitors
04/24/2003WO2003032997A1 Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same
04/24/2003WO2003032996A1 Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists
04/24/2003WO2003032993A1 Use of phosphorodiesterase iv inhibitors
04/24/2003WO2003032991A1 N-aroyl piperazine derivatives as orexin receptor antagonists
04/24/2003WO2003032989A1 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
04/24/2003WO2003032987A1 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032986A1 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032981A1 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
04/24/2003WO2003032980A1 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032972A1 5’-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032971A1 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032970A1 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032969A2 Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
04/24/2003WO2003032965A2 Use of ace inhibitors for reducing type 2 diabetes in high risk patients
04/24/2003WO2003032964A2 Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
04/24/2003WO2003032963A2 Method of reducing type 2 diabetes in high risk patients
04/24/2003WO2003032918A2 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors
04/24/2003WO2003032916A2 Organosulfur inhibitors of tyrosine phosphatases
04/24/2003WO2003032913A2 Methods and compositions for targeting proteins across the blood brain barrier
04/24/2003WO2003032912A2 Treatment of cns disorders using cns target modulators
04/24/2003WO2003032910A2 Carbinols for the treatment of neuropathic dysfunction
04/24/2003WO2003032902A2 Tumor targeted photodiagnostic-phototherapeutic agents
04/24/2003WO2003032901A2 Pathological tissue detection and treatment employing targeted benzoindole optical agents
04/24/2003WO2003032900A2 Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications
04/24/2003WO2003032894A2 Method of monitoring neuroprotective treatment
04/24/2003WO2003032866A2 Detection and treatment of intravascular lesions
04/24/2003WO2003032735A1 Remodeling of tissues and organs
04/24/2003WO2003032727A1 Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
04/24/2003WO2003011887A3 Antisense modulation of apolipoprotein b expression
04/24/2003WO2003011265A3 5-aminolevulinic acid and esters, in combination with another phtosensitizer, as photosensitizing agents in photochemotherapy, and their uses in treating wounds
04/24/2003WO2002098907A3 Cation conducting gabaa receptors and their use
04/24/2003WO2002095016A3 Champ - a cardiac helicase-like factor
04/24/2003WO2002076509A3 Preparation for the prophylaxis of restenosis
04/24/2003WO2002070011A3 Treatment of ppar mediated diseases
1 ... 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 ... 1595